A PYMNTS Company
Antitrust Chronicle<sup>®</sup> – Patents, Drugs & Antitrust

Antitrust Chronicle® – Patents, Drugs & Antitrust

Spring 2014, Volume 4, Number 2

Dear Readers, This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to…

Read More

In this issue

Antitrust Chronicle® – Patents, Drugs & Antitrust
CPI
Oct 1, 2021
APR-14(2)
CPI
Dec 22, 2015
Refusal to Deal Under FDA Imposed Risk Evaluation and Mitigation Strategies (REMS): Economic Considerations
Robert Maness
Apr 29, 2014
When Does Sharing Make Sense?: Antitrust & Risk Evaluation and Mitigation Strategies
Jan Rybnicek
Apr 29, 2014
Defining “Payments”: The First Post-Actavis Battleground in Pharmaceutical Reverse Payments
Lauren Battaglia
Apr 29, 2014
Courts’ Prescription for Reverse-Payment Settlements Still Unknown Almost a Year After FTC v. Actavis
Ankur Kapoor
Apr 29, 2014
The St. Luke’s-Saltzer Antitrust Case: Can Antitrust and Health Care Reform Policies Converge?
Monica Noether
Apr 29, 2014
North Carolina Dental: The Supreme Court and State Action Antitrust Immunity
Jane Willis
Apr 29, 2014
New Jersey District Court Limits Actavis To Cash Payments
Donald Falk
Apr 29, 2014

In case you missed it...



November 2024


October 2024


September 2024
See more Chronicles by year:

Featured News

Microsoft Demands FTC Investigation into Alleged Antitrust Probe Leak
Dec 3, 2024 by

American Express Must Face Class Action Lawsuit, US Judge Rules
Dec 3, 2024 by

Ted Cruz Seeks Probe into European Influence on US AI Laws
Dec 3, 2024 by

Microsoft Faces £1.2 Billion Lawsuit in UK Over Cloud Software Licensing Practices
Dec 3, 2024 by

Bimbo Seeks $2B in Damages from Maple Leaf Foods in Canada Bread Price-Fixing Case
Dec 3, 2024 by